Apr 11, 2022
“These data suggest that vaccine responses are reduced but can be improved by sufficient vaccine/virus exposure,” investigators stated.
seen from United States
seen from Singapore
seen from Malaysia
seen from United States
seen from United States
seen from Singapore
seen from Finland
seen from United States
seen from Russia
seen from China
seen from China
seen from South Korea
seen from Malaysia
seen from Costa Rica
seen from United States
seen from Russia
seen from Türkiye
seen from China
seen from Malaysia
seen from Australia
“These data suggest that vaccine responses are reduced but can be improved by sufficient vaccine/virus exposure,” investigators stated.
Disease Modifying Antirheumatic Drugs - DMARD'S - Rheumatoid Arthritis -...
Rheumatology Therapeutics Market: Global Outlook 2025–2034
The global Rheumatology Therapeutics Market is valued at $51.82 billion in 2025, projected to reach $66.68 billion by 2034, growing at a 2.84% CAGR. This growth is powered by rising autoimmune disorders, expanding biologic therapies, and the integration of AI-driven precision medicine.
Market Highlights
North America leads with 41% share (2024)
Asia Pacific fastest-growing region (2025–2034)
DMARDs dominate drug type (55% in 2024)
Biologic DMARDs expected to grow the fastest
Rheumatoid arthritis (RA) leads disease indication (42% share)
Gout is the fastest-growing segment
Oral therapies hold 60% share; injectables rising quickest
AI Is Redefining Rheumatology
From early diagnosis to treatment response prediction, AI is reshaping autoimmune care.
CMS recognizes AI-based precision tools (e.g., PrismRA)
Global conferences highlight fast-rising digital health interest
AI-enhanced drug discovery → faster biologics, optimized trials
Analytics improve production, supply chains, and patient outcomes
Growth Drivers to Watch
Expanding biologic and biosimilar adoption
Higher investments in biopharma R&D
Surge in clinical trials for next-gen autoimmune drugs
Telemedicine + remote monitoring becoming standard
Increased awareness → earlier diagnosis → better outcomes
Regional Snapshot
North America
Market: $21.25B (2025) → $27.67B (2034)
Strong biologics uptake, advanced clinical practices
U.S. alone: $15.72B in 2025
Asia Pacific
Fastest growth, driven by affordability reforms & rising middle class
China leads RA clinical research (58% of global RA trials)
Europe
High adoption of biosimilars → cost-efficient treatment expansion
Germany anchors regional leadership with >1.8M patients treated annually
Pipeline & R&D Momentum
Over 1,100 RA clinical trials launched since 2018
China surpasses the U.S. in total trials (2024)
$21B invested in autoimmune R&D (2021–2023)
Major 2025 partnerships:
Syneron Bio × AstraZeneca: $3.4B
Earendil Labs × Sanofi: $1.7B
Value Chain Overview
Discovery → Preclinical → Clinical Trials → Regulatory Approval → Manufacturing → Distribution → Patient Care Key players include Pfizer, AbbVie, Roche, Novartis, Eli Lilly, Samsung Biologics, IQVIA, and more.
Spotlight: AbbVie Inc.
Global leader in immunology
Creator of Humira, Rinvoq, Skyrizi
$54B+ annual revenue
Active in precision medicine, AI-assisted drug discovery & next-gen biologics
Market Leaders
Some major companies shaping rheumatology therapeutics: Pfizer • Johnson & Johnson • Amgen • Novartis • UCB • Eli Lilly • Gilead Sciences • Takeda • Roche
Autoimmune Care Is Entering a New Era
Biologics, digital health, AI, and global R&D expansion are transforming patient outcomes — marking the 2025–2034 decade as one of the most innovative phases in rheumatology.
UEGW 2025: risultati clinicamente significativi a 48 settimane con guselkumab in regime sottocutaneo nella colite ulcerosa
Presentati da Johnson & Johnson alla United European Gastroenterology (UEG) Week 2025 i risultati a 48 settimane dello studio di fase 3 ASTRO che ha valutato guselkumab somministrato per via sottocutanea (SC) come terapia di induzione e di mantenimento in adulti con colite ulcerosa (CU) attiva da moderata a grave1. In particolare, questi dati hanno mostrato tassi di remissione clinica ed…
View On WordPress
Psoriasi a placche
La psoriasi è una malattia cronica, dolorosa, deturpante e invalidante per la quale non esiste una cura.[1] È anche la più comune malattia della pelle legata al sistema immunitario che colpisce circa 125 milioni di persone in tutto il mondo.[2] La forma più comune di psoriasi è la psoriasi a placche, che di solito si manifesta con delle aree di pelle ispessita, rossa o infiammata ricoperta da…
View On WordPress
Mycophenolate and Phenylketonurics
In this article, we will discuss Mycophenolate and Phenylketonurics. So, let’s get started. Mycophenolate and Phenylketonurics Mycophenolate Oral Suspension contains aspartame, a source of phenylalanine (0.56 mg phenylalanine/mL suspension). Therefore, care should be taken if Mycophenolate Oral Suspension is administered to patients with phenylketonuria.
View On WordPress
Mycophenolate and Live Vaccines
Mycophenolate and Live Vaccines
In this article, we will discuss Mycophenolate and Live Vaccines. So, let’s get started. Mycophenolate and Live VaccinesDuring treatment with Mycophenolate, the use of live attenuated vaccines should be avoided and patients should be advised that vaccinations may be less effective. Influenza vaccination may be of value. Prescribers should refer to national guidelines for influenza vaccination.
View On WordPress
Mycophenolate and Ciprofloxacin and Amoxicillin plus Clavulanic Acid
Mycophenolate and Ciprofloxacin and Amoxicillin plus Clavulanic Acid
In this article, we will discuss Mycophenolate and Ciprofloxacin and Amoxicillin plus Clavulanic Acid. So, let’s get started. Mycophenolate and Ciprofloxacin and Amoxicillin plus Clavulanic AcidA total of 64 Mycophenolate-treated renal transplant recipients received either oral ciprofloxacin 500 mg bid or amoxicillin plus clavulanic acid 375 mg tid for 7 or at least14 days. Approximately 50%…
View On WordPress